GNI Group Ltd

GNI Group Ltd has a strong liquidity position, with cash and equivalents amounting to ¥16.3 billion, which is significantly higher than its long-term debt of ¥6.02 billion, resulting in a debt-to-equity ratio of 0.16. The company's current ratio of 2.83 indicates a solid ability to meet short-term obligations.

The company's profitability is currently negative, with a net loss of ¥1.12 billion and an operating loss of ¥522 million. Its return on equity is -3.05%, and return on assets is -1.63%, both significantly below the industry median for biotechnology and medical research firms. This suggests that the company is underperforming in terms of generating returns for shareholders and asset utilization.

GNI Group Ltd's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification increases the company's exposure to market-specific risks, particularly in Japan, where it operates.

The company's growth trajectory is uncertain, with no clear revenue growth reported in the latest financial period. Analysts have provided a mean price target of ¥4,400, with a median of ¥4,400, indicating a neutral outlook. The absence of positive revenue growth and ongoing losses suggests that the company may need to implement significant operational or strategic changes to improve its financial performance.

The risk assessment for GNI Group Ltd indicates low liquidity and dilution risks, with no immediate filing-based flags detected. However, the company's negative operating and net income, combined with negative cash flows from operations and free cash flow, suggests that it may need to raise additional capital in the future, which could lead to dilution for existing shareholders.

Recent events, including the latest financial filing, show continued losses and negative cash flows. No material events such as mergers, acquisitions, or major regulatory changes have been reported in the latest available data. The company's financial performance and cash flow position suggest that it is in a challenging phase, requiring strategic adjustments to improve its financial health.

Analysts project 73.6% upside to a mean price target of 4,400 JPY, signaling strong market confidence in future performance.

Revenue grew at a 20.6% CAGR over four years, demonstrating robust top-line expansion despite recent volatility in profitability.

Operating margin ranks in the top quartile of the biotechnology cohort, indicating superior operational efficiency relative to peers.

Return on equity exceeds the cohort median, suggesting better capital utilization efficiency compared to most biotechnology competitors.

Cash conversion ratio is above the 75th percentile of the cohort, highlighting strong ability to convert earnings into cash.

The company faces high credit risk, indicating potential difficulties in meeting financial obligations or securing favorable financing terms.

Debt-to-equity ratio is significantly above the cohort median, suggesting higher financial leverage and associated risk compared to peers.

Revenue ¥5.53B, +3,9% YoY; Operating income −255,9% YoY.

• ▍Revenue ¥5.53B, +3,9% YoY
• ▍Operating income −255,9% YoY
• ▍Net income −301,3% YoY
• ▍Free cash flow −194,8% YoY
• ▍Net margin -38.5%

Revenue ¥7.48B, +16,6% YoY; Operating income −216,2% YoY.

• ▍Revenue ¥7.48B, +16,6% YoY
• ▍Operating income −216,2% YoY
• ▍Net income −1 712,5% YoY
• ▍Free cash flow −749,4% YoY
• ▍Net margin -50.1%

Revenue ¥7.10B, +30,2% YoY; Operating income +17,5% YoY.

• ▍Revenue ¥7.10B, +30,2% YoY
• ▍Operating income +17,5% YoY
• ▍Net income −56,9% YoY
• ▍Free cash flow −35,4% YoY
• ▍Net margin 5.9%

Revenue ¥6.93B, +19,8% YoY; Operating income +21,9% YoY.

• ▍Revenue ¥6.93B, +19,8% YoY
• ▍Operating income +21,9% YoY
• ▍Net income +65,8% YoY
• ▍Free cash flow +15,5% YoY
• ▍Net margin -5.6%

Revenue ¥5.32B; Operating income -¥772.3M.

• ▍Revenue ¥5.32B
• ▍Operating income -¥772.3M
• ▍Net margin -10.0%

Revenue ¥6.42B; Operating income -¥940.5M.

• ▍Revenue ¥6.42B
• ▍Operating income -¥940.5M
• ▍Net margin -3.2%

Revenue ¥5.46B; Operating income ¥580.7M.

• ▍Revenue ¥5.46B
• ▍Operating income ¥580.7M
• ▍Net margin 17.9%

Revenue ¥5.79B; Operating income -¥521.7M.

• ▍Revenue ¥5.79B
• ▍Operating income -¥521.7M
• ▍Net margin -19.4%

Revenue ¥26.84B, +13,7% YoY; Operating income −347,5% YoY.

• ▍Revenue ¥26.84B, +13,7% YoY
• ▍Operating income −347,5% YoY
• ▍Net income −486,4% YoY
• ▍Free cash flow −1 244,8% YoY
• ▍Net margin -15.8%

Revenue ¥23.61B, −9,2% YoY; Operating income −89,3% YoY.

• ▍Revenue ¥23.61B, −9,2% YoY
• ▍Operating income −89,3% YoY
• ▍Net income −86,4% YoY
• ▍Free cash flow −106,9% YoY
• ▍Net margin 4.7%

Revenue ¥26.01B, +49,3% YoY; Operating income +851,3% YoY.

• ▍Revenue ¥26.01B, +49,3% YoY
• ▍Operating income +851,3% YoY
• ▍Net income +1 981,7% YoY
• ▍Free cash flow +454,7% YoY
• ▍Net margin 31.1%

Revenue ¥17.42B, +37,3% YoY; Operating income −15,2% YoY.

• ▍Revenue ¥17.42B, +37,3% YoY
• ▍Operating income −15,2% YoY
• ▍Net income −63,5% YoY
• ▍Free cash flow −461,9% YoY
• ▍Net margin 2.2%